Hormonal
Resmetirom (80-100 mg daily) improves histological MASH resolution and fibrosis in patients with F2-F3 fibrosis without requiring significant weight loss, while also lowering LDL cholesterol.
If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Resmetirom is a new daily pill option. It works by targeting liver-specific thyroid receptors to reduce inflammation and scarring, and it also lowers bad cholesterol. You do not need to lose a lot of weight for it to work on the liver, though diet and exercise are still recommended.
Resmetirom 80 mg and 100 mg achieved MASH resolution in significantly higher proportions than placebo: 25.9% and 29.9% respectively, vs. 9.7% with placebo... Similarly, significantly higher proportions achieved fibrosis improvement by at least one stage without worsening of MASH: 24.2% and 25.9% respectively, vs. 14.2% with placebo... These histological improvements occurred without significant weight loss (-1.8 kg to -1.2 kg in treated arms vs. -0.87 kg with placebo)... LDL cholesterol was significantly reduced after 24 weeks compared with placebo: -12% and -16% in the 80 mg and 100 mg arms respectively, vs. + 1% with placebo
Why this rating
Based on Phase 3 randomized, double-blind, placebo-controlled trial (MAESTRO-NASH).
Source
AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update
Alessio Aghemo et al. · Digestive and Liver Disease · 2026
DOI 10.1016/j.dld.2026.02.014
More from this paper
- Semaglutide (2.4 mg weekly) significantly improves MASH resolution and fibrosis in patients with F2-F3 fibrosis, with benefits extending to significant weight loss and metabolic improvements.Strong
- Tirzepatide demonstrates superior weight reduction compared to Semaglutide 2.4 mg and significant MASH resolution in patients with histologically-proven MASH.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →